C CARSGEN THERAPEUTICS Trademark

Trademark Overview

On Tuesday, May 7, 2024, a trademark application was filed for C CARSGEN THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the C CARSGEN THERAPEUTICS trademark a serial number of 79397815. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Wednesday, December 31, 2025. This trademark is owned by CARSGEN THERAPEUTICS CO., LTD.. The C CARSGEN THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Diagnostic preparations for medical purposes; biological tissue cultures for medical purposes; stem cells for medical purposes; liquid medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; injectable medicinal solutions in the nature of pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint d...
c carsgen therapeutics

General Information

Serial Number79397815
Word MarkC CARSGEN THERAPEUTICS
Filing DateTuesday, May 7, 2024
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateWednesday, December 31, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, January 20, 2026

Trademark Statements

NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesDiagnostic preparations for medical purposes; biological tissue cultures for medical purposes; stem cells for medical purposes; liquid medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; injectable medicinal solutions in the nature of pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; drugs for medical purposes in the nature of pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; vaccines; biological preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases for medical purposes; blood preparations, namely, blood for medical purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, June 28, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCARSGEN THERAPEUTICS CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCN

Trademark Events

Event DateEvent Description
Thursday, June 20, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, June 28, 2024LIMITATION FROM ORIGINAL APPLICATION ENTERED
Friday, April 18, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 18, 2025APPLICATION FILING RECEIPT MAILED
Monday, April 21, 2025ASSIGNED TO EXAMINER
Monday, April 21, 2025NON-FINAL ACTION WRITTEN
Tuesday, April 22, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, July 4, 2025REFUSAL PROCESSED BY MPU
Friday, July 4, 2025NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, July 26, 2025REFUSAL PROCESSED BY IB
Wednesday, November 19, 2025NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, November 19, 2025NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, December 5, 2025NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sunday, December 14, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, December 14, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sunday, December 14, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, December 14, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, December 14, 2025TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, December 17, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 17, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 17, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 22, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 14, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Related Keywords

therapeutics carsgen diseases system cardiovascular disorders chronic medical purposes digestive inflammatory joint